Skip to main content
. 2019 Nov 21;20:637. doi: 10.1186/s13063-019-3740-6

Fig. 2.

Fig. 2

Flow chart showing the study design of the open-label extension phase (OLE) of the tamoxifen in Duchenne muscular dystrophy (TAMDMD) study. IMP investigational medicinal product, TAM tamoxifen